Amsterdam Investigator–initiateD Absorb strategy all-comers trial (AIDA trial): A clinical evaluation comparing the efficacy and performance of ABSORB everolimus-eluting bioresorbable vascular scaffold strategy vs the XIENCE family (XIENCE PRIME or XIENCE Xpedition) everolimus-eluting coronary stent strategy in the treatment of coronary lesions in consecutive all-comers: Rationale and study design - 20/01/14
Résumé |
Background |
The Absorb everolimus-eluting bioresorbable vascular scaffold (AbsorbBVS) is a completely resorbable device engineered to overcome the limitations of permanent metallic stents, providing temporary scaffolding and antiproliferative drug delivery for the treatment of obstructive coronary artery disease.
Methods |
The objective of the AIDA trial is to evaluate the efficacy and performance in an contemporary all-comer population of the AbsorbBVS strategy vs the XIENCE family everolimus-eluting metallic coronary stent system in the treatment of coronary lesions. The AIDA trial is a prospective, randomized (1:1), active-control, single-blinded, all-comer, noninferiority trial. A total of 2,690 subjects will be enrolled with broad inclusion and limited exclusion criteria according to the “Instructions for Use” of the AbsorbBVS strategy. The study population includes both simple and complex lesions, in patients with stable and acute coronary syndrome. The follow-up continues for 5years. The primary end point of the trial is target vessel failure, defined as the composite of cardiac death, myocardial infarction, and target vessel revascularization, at 2years. This study is registered on ClinicalTrials.gov with number NCT01858077.
Conclusion |
The AIDA trial will provide the first randomized direct comparison between the everolimus-eluting bioresorbable vascular scaffold and the everolimus-eluting metallic stent in contemporary percutaneous coronary intervention practice.
Le texte complet de cet article est disponible en PDF.Plan
| Clinical trials registration: ClinicalTrials.gov no. NCT01858077. |
Vol 167 - N° 2
P. 133-140 - février 2014 Retour au numéro
Article précédent
- TRIple pill vs Usual care Management for Patients with mild-to-moderate Hypertension (TRIUMPH): Study protocol
- Abdul Salam, Ruth Webster, Kavita Singh, Sudha Kallakuri, Anthony Rodgers, Dorairaj Prabhakaran, Pallab K. Maulik, Stephen Jan, Simon Thom, Nitish Naik, Rama Guggilla, Vanessa Selak, Anushka Patel
- Effect of A Reduction in glomerular filtration rate after NEphrectomy on arterial STiffness and central hemodynamics: Rationale and design of the EARNEST study
- William E. Moody, Laurie A. Tomlinson, Charles J. Ferro, Richard P. Steeds, Patrick B. Mark, Daniel Zehnder, Charles R. Tomson, John R. Cockcroft, Ian B. Wilkinson, Jonathan N. Townend
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?